Lawrence Steinman net worth and biography

Lawrence Steinman Biography and Net Worth

Director of Pasithea Therapeutics

Lawrence is a professor of neurology and neurological sciences, pediatrics and genetics at Stanford Medical School, where he leads a research team that focuses on the pathogenesis of autoimmune diseases. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation, leading to the development of the drug Tysabri.

Lawrence received his doctoral degree from Harvard Medical School, and he was a post-doctoral fellow in chemical immunology at the Weizmann Institute of Science in Israel. He has received many honors and awards, including the John M. Dystel Prize from the American Academy of Neurology and the National MS Society for his research on multiple sclerosis (MS), the Charcot Prize for Lifetime Achievement in MS research and the Cerami Prize for Translational Research. He has twice been awarded the Senator Jacob Javits Neuroscience Investigator Award by the National Institute of Neurological Diseases and Stroke. Lawrence is a member of the National Academy of Sciences and the National Academy of Medicine.

What is Lawrence Steinman's net worth?: The estimated net worth of Lawrence Steinman is at least $98.85 thousand as of November 28th, 2025. Dr. Steinman owns 199,691 shares of Pasithea Therapeutics stock worth more than $98,847 as of October 2nd. This net worth estimate does not reflect any other assets that Dr. Steinman may own. Learn More about Lawrence Steinman's net worth.
How do I contact Lawrence Steinman?: The corporate mailing address for Dr. Steinman and other Pasithea Therapeutics executives is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. Pasithea Therapeutics can also be reached via phone at 702-514-4174 and via email at [email protected]. Learn More on Lawrence Steinman's contact information.
Has Lawrence Steinman been buying or selling shares of Pasithea Therapeutics?: Lawrence Steinman has not been actively trading shares of Pasithea Therapeutics within the last three months. Most recently, on Friday, November 28th, Lawrence Steinman bought 133,333 shares of Pasithea Therapeutics stock. The stock was acquired at an average cost of $0.75 per share, with a total value of $99,999.75. Following the completion of the transaction, the director now directly owns 199,691 shares of the company's stock, valued at $149,768.25. Learn More on Lawrence Steinman's trading history.
Are insiders buying or selling shares of Pasithea Therapeutics?: In the last twelve months, Pasithea Therapeutics insiders bought shares 3 times. They purchased a total of 199,999 shares worth more than $149,999.25. The most recent insider tranaction occured on November, 28th when CEO Tiago Marques bought 33,333 shares worth more than $24,999.75. Insiders at Pasithea Therapeutics own 1.5% of the company. Learn More about insider trades at Pasithea Therapeutics.
Information on this page was last updated on 11/28/2025.

Lawrence Steinman Insider Trading History at Pasithea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/28/2025	Buy	133,333	$0.75	$99,999.75	199,691
6/2/2023	Buy	1,500	$8.60	$12,900.00	66,358

Lawrence Steinman Buying and Selling Activity at Pasithea Therapeutics

Pasithea Therapeutics Company Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Today's Range

Now: $0.48

$0.47

$0.51

50 Day Range

MA: $0.51

$0.44

$0.60

2 Week Range

Now: $0.48

$0.28

$2.06

Volume

48,874 shs

Average Volume

459,445 shs

Market Capitalization

$16.17 million

P/E Ratio

N/A

Dividend Yield